About Impella® Heart Pumps

 

What are Impella Heart Pumps?

Impella, the world’s smallest heart pump, is a support system of percutaneous catheter-based technology offering hemodynamic support to the heart. Impella has been treating patients in the United States since 2008. Impella heart pumps allow the heart to rest and recover by temporarily assisting the pumping function of the heart to efficiently deliver blood and oxygen to the entire body.

Impella is the only U.S. FDA-approved percutaneous heart pump technology indicated for patients with severe coronary artery disease requiring high-risk PCI or AMI cardiogenic shock.

Why is Impella Important?

White illustrated icon of two hands surrounding a heart on a red circle background

Supports Your Heart

Protected PCI with Impella ensures blood flow is maintained to critical organs enabling your physician to perform a complete and optimized procedure, decreasing the likelihood of repeat procedures and multiple hospital stays.

White illustrated icon of a heart with a heartbeat in the middle on a red circle background

Improved Quality of Life

In a randomized controlled trial, 8-in-10 patients treated with Impella heart pumps experienced reduction in heart failure symptoms or improvement in heart function.5,8

Stories of Recovery with Impella

 

Chris Decker

Retired State Trooper Returns to His Active Lifestyle After Receiving Impella Support

 

Morgan Wright

American Ninja Warrior Competitor and Family Man Survives Cardiogenic Shock

 

Pamela Kerr

Sydney Woman Celebrates 90th Birthday After Protected PCI Procedure With Impella

Portrait of Impella patient Babu Eladasari and his wife with a teal background with a hash pattern overlay

“I’m back to normal function. Actually, a little better than before. This is a second chance in life.”

- BABU ELADASARI

References

  1. Dangas, G.D., et al. (2014). Am J Cardiol, 113(2), 222-228. 
  2. Maini, B., et al. (2014). Catheter Cardiovasc Interv, 83(6), E183-E192. 
  3. Gregory, D., et al. (2013). J Manag Care Med, 16(1), 61-69.  
  4. Gregory, D., et al. (2013). Am Health Drug Benefits, 6(2), 88-99.
  5. O’Neill, W.W., et al. (2012). Circulation, 126(14), 1717-1727.
  6. O’Neill, W.W., et al. (2014). J Interviev Cardiol, 27(1), 1-11.
  7. Roos, J.B., et al. (2013). J Med Econ, 16(3), 3381-390.
  8. PROTECT II Data on File
 

NPS-1319